Jiangsu Pacific Meinuoke Biopharmaceutical 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
9 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
meplazumab / Jiangsu Pacific Meinuoke Biopharmaceutical, Air Force Medical University
NCT05679492: Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19

Withdrawn
3
1320
RoW
Meplazumab foe injection, Normal saline
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
09/23
12/23
NCT05813587: To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19

Completed
3
121
RoW
Meplazumab for injection, Normal saline
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Post-COVID-19
09/23
10/23
NCT05679479: Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

Completed
3
108
RoW
Meplazumab for injection, Normal saline
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
01/24
04/24
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19

Completed
2/3
150
RoW
Meplazumab for Injection, Sterile normal saline (0.9%)
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Covid19
09/22
10/22
NCT04586153: Study to Assess the Effect of Meplazumab on COVID-19

Completed
2/3
174
RoW
Meplazumab for Injection, Sterile normal saline (0.9%)
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
12/22
12/22
NCT06040346: Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Active, not recruiting
2
60
RoW
Meplazumab for Injection
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Malaria
08/25
10/25
REC-SAFECAD, NCT06572267: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Recruiting
2
18
RoW
Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline
Xijing Hospital
Coronary Artery Disease
09/25
03/26
NCT04327310: Clinical Study of Meplazumab to Treat With Malaria

Withdrawn
1
112
NA
Meplazumab for Injection, Meplazumab, Sterile normal saline (0.9%)
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Malaria (Plasmodium Falciparum)
12/23
03/24
metuzumab / Jiangsu Pacific Meinuoke Biopharmaceutical
DynastyBreast01, CTR20233403: A Phase III, Multicenter, Open-label, Randomized Controlled Study to Evaluate DB-1303 Versus Enmetuzumab (T-DM1) in Patients With HER2-Positive Unresectable/Metastatic Breast Cancer Previously Treated with Trastuzumab and Taxanes (Dynasty-Breast01)

Ongoing
3
224
China
Kadcyla (ado-trastuzumab emtansine) - Roche, BNT323 - BioNTech
Yingen Biopharmaceutical (Suzhou) Co., Ltd
HER2-positive unresectable/metastatic breast cancer
 
 
CAR-TG / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
CAR-TH / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
ADC-1 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC003 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC004 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC005 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC006 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC007 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC008 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
anti-RANKL monoclonal antibody / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
tocilizumab biosimilar / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
adalimumab biosimilar / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
meplazumab / Jiangsu Pacific Meinuoke Biopharmaceutical, Air Force Medical University
NCT05679492: Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19

Withdrawn
3
1320
RoW
Meplazumab foe injection, Normal saline
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
09/23
12/23
NCT05813587: To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19

Completed
3
121
RoW
Meplazumab for injection, Normal saline
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Post-COVID-19
09/23
10/23
NCT05679479: Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19

Completed
3
108
RoW
Meplazumab for injection, Normal saline
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
01/24
04/24
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19

Completed
2/3
150
RoW
Meplazumab for Injection, Sterile normal saline (0.9%)
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Covid19
09/22
10/22
NCT04586153: Study to Assess the Effect of Meplazumab on COVID-19

Completed
2/3
174
RoW
Meplazumab for Injection, Sterile normal saline (0.9%)
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
COVID-19
12/22
12/22
NCT06040346: Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum

Active, not recruiting
2
60
RoW
Meplazumab for Injection
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Malaria
08/25
10/25
REC-SAFECAD, NCT06572267: Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Recruiting
2
18
RoW
Mepolizumab low dose group, Mepolizumab middle dose group, Mepolizumab high dose group, Saline
Xijing Hospital
Coronary Artery Disease
09/25
03/26
NCT04327310: Clinical Study of Meplazumab to Treat With Malaria

Withdrawn
1
112
NA
Meplazumab for Injection, Meplazumab, Sterile normal saline (0.9%)
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Malaria (Plasmodium Falciparum)
12/23
03/24
metuzumab / Jiangsu Pacific Meinuoke Biopharmaceutical
DynastyBreast01, CTR20233403: A Phase III, Multicenter, Open-label, Randomized Controlled Study to Evaluate DB-1303 Versus Enmetuzumab (T-DM1) in Patients With HER2-Positive Unresectable/Metastatic Breast Cancer Previously Treated with Trastuzumab and Taxanes (Dynasty-Breast01)

Ongoing
3
224
China
Kadcyla (ado-trastuzumab emtansine) - Roche, BNT323 - BioNTech
Yingen Biopharmaceutical (Suzhou) Co., Ltd
HER2-positive unresectable/metastatic breast cancer
 
 
CAR-TG / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
CAR-TH / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
ADC-1 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC003 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC004 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC005 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC006 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC007 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
PMC008 / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
anti-RANKL monoclonal antibody / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
tocilizumab biosimilar / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found
adalimumab biosimilar / Jiangsu Pacific Meinuoke Biopharmaceutical
No trials found

Download Options